Increased expression and altered subcellular distribution of PKC-δ and PKC-ɛ in pulmonary arteries exposed to hypoxia and 15-HETE

Prostaglandins Other Lipid Mediat. 2010 Nov;93(3-4):84-92. doi: 10.1016/j.prostaglandins.2010.06.008. Epub 2010 Jul 6.

Abstract

15-hydroxyeicosatetraenoic acid (15-HETE), a product of arachidonic acid (AA) catalyzed by 15-lipoxygenase (15-LOX), is an important mediator of hypoxic pulmonary vasoconstriction (HPV). We have previously reported that 15-HETE-induced pulmonary vasoconstriction occurs via protein kinase C (PKC) pathway, however, the role of PKC isoforms involved in 15-HETE-induced pulmonary vasoconstriction remains poorly understood. To examine the potential role of PKC-δ and PKC-ɛ isoforms that appear to be involved in 15-HETE-induced pulmonary artery (PA) contraction, a combination of immunofluorescence, western blotting, semi-quantitative PCR and functional contractile tension approaches on rat PA rings were utilized. We found that 15-HETE activates the translocation of PKC-δ and PKC-ɛ from the cytoplasm to the membranes of pulmonary arterial smooth muscle cells (PASMCs). However, the alteration was significantly reversed by nordihydroguairetic acid (NDGA), a 15-LOX inhibitor which blocked the formation of endogenous 15-HETE. Both endogenous and exogenous 15-HETE enhanced the expression of PKC-δ and PKC-ɛ in PASMCs exposure to hypoxia. The PKC inhibitor Gö6983 and rottlerin (PKC-δ selective), and the inhibitor selective for PKC-ɛ peptide significantly attenuated constriction effect of 15-HETE on isolated PA rings of rats maintained for 9 days in hypoxic environments (FiO(2)=0.12) compared with siblings rats under normoxia. Thus, these findings indicate that PKC-δ and PKC-ɛ contributing to hypoxic pulmonary artery contraction elicited by 15-HETE.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Membrane / drug effects
  • Cell Membrane / metabolism
  • Cytoplasm / drug effects
  • Cytoplasm / metabolism
  • Gene Expression Regulation, Enzymologic / drug effects*
  • Hydroxyeicosatetraenoic Acids / antagonists & inhibitors
  • Hydroxyeicosatetraenoic Acids / pharmacology*
  • Hypoxia / enzymology
  • Hypoxia / metabolism*
  • Intracellular Space / drug effects
  • Intracellular Space / enzymology
  • Intracellular Space / metabolism*
  • Male
  • Myocytes, Smooth Muscle / cytology
  • Myocytes, Smooth Muscle / drug effects
  • Myocytes, Smooth Muscle / metabolism
  • Protein Kinase C-delta / antagonists & inhibitors
  • Protein Kinase C-delta / genetics
  • Protein Kinase C-delta / metabolism*
  • Protein Kinase C-epsilon / antagonists & inhibitors
  • Protein Kinase C-epsilon / genetics
  • Protein Kinase C-epsilon / metabolism*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Transport / drug effects
  • Pulmonary Artery / cytology
  • Pulmonary Artery / drug effects*
  • Pulmonary Artery / metabolism
  • Pulmonary Artery / physiology
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Wistar
  • Vasoconstriction / drug effects

Substances

  • Hydroxyeicosatetraenoic Acids
  • Protein Kinase Inhibitors
  • RNA, Messenger
  • 15-hydroxy-5,8,11,13-eicosatetraenoic acid
  • Protein Kinase C-delta
  • Protein Kinase C-epsilon